Učitavanje...
Recombinant human erythropoietin versus placebo or no treatment for the anaemia of chronic kidney disease in people not requiring dialysis
BACKGROUND: Treatment with recombinant human erythropoietin (rHuEPO) in dialysis patients has been shown to be highly effective in terms of correcting anaemia and improving quality of life. There is debate concerning the benefits of rHuEPO use in predialysis patients which may accelerate the deterio...
Spremljeno u:
| Izdano u: | Cochrane Database Syst Rev |
|---|---|
| Glavni autori: | , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
John Wiley & Sons, Ltd
2016
|
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7144724/ https://ncbi.nlm.nih.gov/pubmed/26790135 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/14651858.CD003266.pub3 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|